saf-312
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2009 (NCT00986882)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Vanilloid receptorINHIBITOR
TRPV1 inhibitor
Indication: Postoperative Pain, Neurogenic Bladder Disorder. Ph2 study terminated, development halted?
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3544953 ↗
Also known as
- saf312
- saf312
- saf312
- saf-312
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04630158 | Phase 2 | Apr 21, 2021 | Novartis |
| NCT02961062 | Phase 2 | Nov 1, 2016 | Novartis |
| NCT01598103 | Phase 2 | Jan 1, 2012 | Novartis |
| NCT00986882 | Phase 2 | Sep 1, 2009 | Novartis |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 4 | 4 | 1 | 2009 |
1 organizations
Page 1 / 1